Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lactobacillus rhamnosus JL-1 + soy protein isolate
- Development stage
- Unknown
- Lead developer
- Jianhu County People's Hospital
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Recombinant Proteins and Enzymes, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Lactobacillus rhamnosus JL-1 + soy protein isolate is a combination therapeutic consisting of a specific probiotic strain and a purified protein source. Developed by Jianhu County People's Hospital, it is primarily investigated for the treatment of non-alcoholic fatty liver disease (NAFLD). The mechanism of action involves the synergistic modulation of the gut-liver axis; Lactobacillus rhamnosus JL-1 alters the gut microbiota to reduce endotoxemia and systemic inflammation, while soy protein isolate provides bioactive peptides that regulate lipid metabolism and reduce hepatic fat accumulation. This combination aims to improve liver function and metabolic parameters in patients with NAFLD by targeting both the microbiome and hepatic lipid processing pathways.
- Other names
- JL-1 + SPI
02
Targets
AMPK (Adenosine monophosphate–activated protein kinase)PPARG (Peroxisome proliferator-activated receptor gamma)TLR4 (Toll-like receptor 4)NR1H3 (Liver X receptor beta)
Beyond the preview
Go deeper on lactobacillus rhamnosus JL-1 + soy protein isolate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lactobacillus rhamnosus JL-1 + soy protein isolate.